Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS RECEIVES HEALTH CANADA APPROVAL TO COMMERCIALIZE ITS FFR PRODUCTS

21 July 2015

Quebec City, Quebec, July 21, 2015 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) today announced it has received Health Canada’s approval to commercialize the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve (“FFR”). FFR is used to optimize the diagnosis and guide the treatment of patients with coronary heart disease….

Read more

OPSENS – RESULTS FOR THIRD QUARTER 2015

2 July 2015

Quebec City, Quebec, July 2, 2015 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) today released results for its third quarter ended May 31, 2015. HIGHLIGHTS OF THE THIRD QUARTER 2015 Receipt of 510 (k) clearance from the U.S. Food and Drug Administration (“FDA”) for commercialisation of the OptoWire and OptoMonitor, Opsens’ products to…

Read more